We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ZENA:NASDAQZenaTech, Inc. Analysis

Data as of 2026-05-12 - not real-time

$1.99

Latest Price

8/10Risk

Risk Level: High

Executive Summary

ZenaTech’s stock is trading at $1.99, well below its 20‑day SMA of $2.13 and 50‑day SMA of $2.24, with the MACD in bearish territory and RSI hovering around 42, indicating limited upward momentum and a price perched near the identified support of $1.91. Volatility is extreme, with a 30‑day swing of over 93% and a beta of 2.27, suggesting the share price can move sharply on any news or market shift. Recent news highlights a 558% YoY revenue surge to $12.9 million and a $10 million contribution from the Drone‑as‑a‑Service (DaaS) line, supported by an acquisition expanding AI autonomy in the Asia‑Pacific region. Despite this top‑line growth, the company reports negative operating cash flow, a -70% max drawdown, and a heavily leveraged balance sheet with debt exceeding $21 million. The consensus target price of $6.93 implies a potential upside of roughly 250%, but the fundamentals—negative EPS, negative book value, and a forward PE of -8—signal substantial downside risk. Investors must weigh the attractive growth narrative against the precarious financial health and high market risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish technical indicators (price below SMAs, MACD negative)
  • Proximity to near‑term support level
  • Extreme short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth driven by DaaS and AI acquisitions
  • Target price suggests substantial upside
  • Expanding market presence in Asia‑Pacific infrastructure

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Long‑term potential in enterprise SaaS and quantum computing
  • Continued cash‑flow deficits and high debt load
  • Need for sustainable profitability to justify valuation

Key Metrics & Analysis

Financial Health

Revenue Growth670.80%
P/E Ratio-8.0
ROE-100.73%
ROA-23.55%
Debt/Equity31.57
P/B Ratio-9.9
Op. Cash Flow$-35461668
Free Cash Flow$-40675456
Industry P/E39.0

Technical Analysis

TrendBearish
RSI42.0
Support$1.91
Resistance$2.59
MA 20$2.13
MA 50$2.24
MA 200$3.73
MACDBearish
VolumeStable
Fear & Greed Index87.96

Valuation

Target Price$6.93
Upside/Downside248.39%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta2.27
Volatility93.10%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.